TipRanks

Thu, Jun 19, 2025, 7:10 AM1 min read

Alnylam (ALNY) Pharmaceuticals announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. “I could not be more excited for Pushkal to take the helm of the combined R&D organization, given his strategic vision, operational excellence and impressive track record building and steering an industry-leading, innovative drug development organization that has delivered a new class of medicines to the world,” said Yvonne Greenstreet, M.D., CEO. Garg joined Alnylam in 2014 to build and lead the company’s Development group.

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>

>;elm:context_link;itc:0;sec:content-canvas" href="https://www.tipranks.com/screener/analysts-top-stocks/?type=stockAnalysisLanding&utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">See the top stocks recommended by analysts >>

Read More on ALNY:

Disclaimer & DisclosureReport an Issue

• Alnylam price target raised to $338 from $330 at JPMorgan

• Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections

• Alnylam receives European Commission approval of AMVUTTRA

• Alnylam Pharma’s Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook

• Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma